Sales of Pfizer's best-selling vaccine may soon be getting bigger. The European Medicines Agency (EMA) has accepted the company's application to expand the label on Prevenar 13 in adults to include the prevention of pneumonia caused by the 13 pneumococcal serotypes the vaccine contains.
Pfizer has cleared the decks of a marketing scandal that it inherited with its 2009 acquisition of Wyeth. The New York drugmaker will pay $35 million to 41 states and the District of Columbia to settle a case accusing it of pushing a kidney transplant drug for off-label uses.
A couple of things happened this past week to set off new chatter about a Pfizer megadeal. First, GlaxoSmithKline posted disappointing earnings and cut its full-year forecast, sending its stock into the dumpster--and its market cap tumbling. Then, Berenberg analysts issued an investor note extolling the potential virtues of a Pfizer-GlaxoSmithKline combo. Let the speculation continue.
Dream come true time for Pfizer and its Nexium 24HR brand team. No sooner had the drugmaker signed Rascal Flatts to rep the new OTC version of the heartburn drug than People magazine came calling. With the tough questions.
In recent years it's been the big biotechs in the U.S. which have registered approvals for the drugs most likely to succeed on the market. But in reviewing EvaluatePharma's recent picks for top Phase III drugs, it's interesting to see some prominent positions among the Big Pharma crowd. Read the full report >>
Labor issues at a Pfizer plant in Thane, India, have led the company to lock employees out of the facility after workers were said to have tried to stop production and threatened managers.
Pfizer is picking up a "portion" of a Baxter International vaccine manufacturing facility in Orth, Austria, as part of a $635 million deal to buy that company's marketed vaccine portfolio.
No news isn't good or bad for Pfizer deal-watchers. It's just no news. Anyone hoping for a halfway-clear idea of CEO Ian Read's next buyout move was disappointed after Tuesday's second-quarter earnings call with analysts.
Prevnar's lonely days are over. Pfizer is finally beefing up beyond its best-selling franchise--a long-stated objective of CEO Ian Read's--nabbing Baxter's marketed vaccines portfolio in a $635 million deal.
Looks like Pfizer's finally getting the vaccines expansion it's been hankering for. The company agreed to pick up Baxter's marketed vaccines portfolio for $635 million, building up its own business as the Illinois healthcare company slims down for a pharma unit spinoff next year.